$102.86
+6.84 (+7.12%)
Open$97.99
Previous Close$96.02
Day High$103.78
Day Low$96.05
52W High$115.52
52W Low$25.23
Volume—
Avg Volume886.6K
Market Cap6.36B
P/E Ratio—
EPS$-2.46
SectorBiotechnology
Analyst Ratings
Strong Buy
20 analysts
Price Target
-79.9% upside
Current
$102.86
$102.86
Target
$20.70
$20.70
$16.39
$20.70 avg
$27.30
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 372.50M | 351.85M | 301.99M |
| Net Income | -104,674,461 | -84,234,881 | -79,583,487 |
| Profit Margin | -28.1% | -23.9% | -26.4% |
| EBITDA | -120,858,001 | -107,157,018 | -93,330,324 |
| Free Cash Flow | -75,919,374 | -55,757,162 | -73,499,960 |
| Rev Growth | -6.8% | +18.4% | +6.2% |
| Debt/Equity | 0.83 | 0.74 | 0.81 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $291.31 | +1.07% | 49.3 | 509.50B |
| AMGN | Amgen Inc | $460.42 | +0.03% | 26.5 | 248.84B |
| GILD | Gilead Sciences Inc | $166.89 | -0.41% | — | 208.28B |
| VRTX | Vertex Pharmaceuticals Inc | $547.09 | +0.85% | 34.5 | 137.12B |
| REGN | Regeneron Pharmaceuticals | $904.35 | +0.16% | 19.4 | 93.39B |
| ALNY | Alnylam Pharmaceuticals Inc | $155.94 | -0.46% | 7.7 | 20.98B |